Geron (GERN) Rockets 50% After Stem Cell Trial Cleared By FDA
Get Alerts GERN Hot Sheet
Join SI Premium – FREE
Geron Corporation (Nasdaq: GERN) is continuing to rocket higher following news this morning that the FDA has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. Geron said this is the world's first human clinical trial of embryonic stem cell-based therapy. The stock is now up 50%.
Geron competitors are also higher on the news: Aastrom Biosciences, Inc. (Nasdaq: ASTM) is up 30% and StemCells Inc. (Nasdaq: STEM) is up 30%.
Geron competitors are also higher on the news: Aastrom Biosciences, Inc. (Nasdaq: ASTM) is up 30% and StemCells Inc. (Nasdaq: STEM) is up 30%.
You May Also Be Interested In
- SEC Confirms Game Service Roblox (RBLX) Part Of ‘Active Investigation’ - Bloomberg
- Jefferies on Workday (WDAY): 'attractive valuation'
- Apple shares fall premarket after report on policies under China’s antitrust probe
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!